Ethyl 4-(4-ethylphenoxy)-3-oxobutanoate | 1225803-77-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: Ethyl 4-(4-ethylphenoxy)-3-oxobutanoate
• CAS: 1225803-77-9
• 化学式: C₁₄H₁₈O₄
• mdl: MFCD16326883
• 分子量: 250.295
• InChiKey: ISWGSFFRQGWDKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Ethyl 4-(4-ethylphenoxy)-3-oxobutanoate 、 5-(三氟甲基)-4H-1,2,4-噻唑-3-胺 在 溶剂黄146 作用下， 反应 0.33h， 生成 5-[(4-ethylphenoxy)methyl]-2-(trifluoromethyl)-1H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one
  参考文献：
  名称：

  [EN] INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP)
  [FR] INHIBITEURS DE LA PROTÉINE DE LIAISON AUX ACIDES GRAS (FABP)

  摘要：

  本发明涉及新型杂环化合物作为脂肪酸结合蛋白（"FABP"）抑制剂，包括该杂环化合物的药物组合物以及利用该化合物治疗或预防心血管疾病、代谢紊乱、肥胖或与肥胖相关的疾病、糖尿病、血脂异常、糖尿病并发症、糖耐量受损或空腹血糖受损的用途。本发明的一个示例化合物如下所示：（I）

  公开号：

  WO2010056631A1
• 作为产物：
  描述：

  4-乙基苯酚 、 4-氯乙酰乙酸乙酯 在 potassium hydroxide 作用下， 以 二甲基亚砜 为溶剂， 以67%的产率得到Ethyl 4-(4-ethylphenoxy)-3-oxobutanoate
  参考文献：
  名称：

  [EN] INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP)
  [FR] INHIBITEURS DE LA PROTÉINE DE LIAISON AUX ACIDES GRAS (FABP)

  摘要：

  本发明涉及新型杂环化合物作为脂肪酸结合蛋白（"FABP"）抑制剂，包括该杂环化合物的药物组合物以及利用该化合物治疗或预防心血管疾病、代谢紊乱、肥胖或与肥胖相关的疾病、糖尿病、血脂异常、糖尿病并发症、糖耐量受损或空腹血糖受损的用途。本发明的一个示例化合物如下所示：（I）

  公开号：

  WO2010056631A1

文献信息

• INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP)
  申请人：Shipps, JR. Gerald W.

  公开号：US20110237575A1

  公开（公告）日：2011-09-29

  The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below: (I)

  本发明涉及新型杂环化合物作为脂肪酸结合蛋白（“FABP”）抑制剂，包括所述杂环化合物的制药组合物以及用于治疗或预防心血管疾病、代谢紊乱、肥胖或肥胖相关疾病、糖尿病、血脂异常、糖尿病并发症、糖耐量受损或空腹血糖受损的化合物的用途。本发明的一种说明性化合物如下：（I）
• ADME-Guided Design and Synthesis of Aryloxanyl Pyrazolone Derivatives To Block Mutant Superoxide Dismutase 1 (SOD1) Cytotoxicity and Protein Aggregation: Potential Application for the Treatment of Amyotrophic Lateral Sclerosis
  作者：Tian Chen、Radhia Benmohamed、Jinho Kim、Karen Smith、Daniel Amante、Richard I. Morimoto、Donald R. Kirsch、Robert J. Ferrante、Richard B. Silverman

  DOI：10.1021/jm2014277

  日期：2012.1.12

  Amyotrophic lateral sclerosis (ALS) is an orphan neurodegenerative disease currently without a cure: The arylsulfanyl pyrazolone (ASP) scaffold was one of the active scaffolds identified in a cell-based high throughput screening assay targeting mutant Cu/Zn superoxide dismutase 1 (SOD 1) induced toxicity and aggregation as a marker for ALS. The initial ASP hit compounds were potent and had favorable ADME properties but had poor microsomal and plasma stability. Here, we identify the microsomal metabolite and describe synthesized analogues of these ASP compounds to address the rapid metabolism. Both in vitro potency and pharmacological properties of the ASP scaffold have been dramatically improved via chemical modification to the corresponding sulfone and ether derivatives. One of the ether analogues (13), with superior potency and in vitro pharmacokinetic properties, was tested in vivo for its pharmacokinetic profile, brain penetration, and efficacy in an ALS mouse model. The analogue showed sustained blood and brain levels in vivo and significant activity in the mouse model of ALS, thus validating the new aryloxanyl pyrazolone scaffold as an important novel therapeutic lead for the treatment of this neurodegenerative disorder.
• US8815875B2
  申请人：——

  公开号：US8815875B2

  公开（公告）日：2014-08-26